Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | FDA Compounding Enforcement Starting Over – Again; MOU Withdrawn, New Rulemaking Will Begin

February 24, 2022

Unger Unplugged: FDA Needs Accelerated Approval To “Take More Chances” – But Also A Clear Path To Withdrawal, Ex-Office Director Says

February 23, 2022

Prevision Policy Clips | Continuous Direct Compression Manufacturing Process Is First “Graduate” Of FDA Emerging Technology Program

February 23, 2022

Prevision Policy Clips | Third Time’s A Charm? Mallinckrodt Terlipressin Receives Third Complete Response Letter From FDA

February 22, 2022

Prevision Policy Clips | Deadlock FTC Vote Means No PBM Study On How Business Practices Impact Drug Prices…For Now

February 18, 2022

Biosimilar First-Cycle Approvals Up Under BSUFA II; Oncologic And Hematologic Indications Lag Compared To Others

February 17, 2022

Prevision Policy Clips | ARPA-H Odds Of Landing Within NIH Increase With Naming Of Francis Collins As Science Advisor To President Biden

February 17, 2022

Avenue’s Road To Market Still Blocked For Tramadol IV After Advisory Committee Rejects Appeal; Vocal Minority Supports Access To New Option, But Risky For FDA To Listen

February 16, 2022

Prevision Policy Clips | Amylyx’ ALS Treatment AMX0035 Headed To FDA Advisory Committee March 30

February 16, 2022

Post-COVID FDA: Commissioner Califf’s First Priorities Of Improving Morale, Inspections Will Have To Be Balanced Against Political Promises

February 15, 2022

RWE Guidance On Regulatory Decision-Making: FDA Stresses Clarity On “Role” Of Evidence In Development Program, Fit-For-Purpose Data

February 15, 2022

Prevision Policy Clips | FDA Nominee Robert Califf Set To Clear Senate

February 15, 2022

Humira Biosimilar Competition Heads AAM Medicare Objectives; Clearing Inspection Backlog Also Priority For Generics/Biosimilars Industry

February 14, 2022

Prevision Policy Clips | Pfizer/BioNTech Pediatric COVID Vaccine Delayed Until At Least April

February 14, 2022

Avenue IV Tramadol Appeal Heads To FDA Committee: Outcome May Hinge On European Safety Experience

February 11, 2022

Prevision Policy Clips | FDA Nominee Califf Appears Set For Confirmation Vote In Senate

February 11, 2022

Lilly Plan To Disrupt Anti-PD1 Market Blows Up: Advisory Committee Rejection Of Sintilimab Suggests Damaged Relationship With FDA

February 10, 2022

Prevision Policy Clips | Accelerated Approval Confirmatory Trial Cleanup Coming, Califf Promises

February 10, 2022

FDA Acute Pain Drug Development Guidance Outlines Three “Opioid-Sparing” Claims – But Sets High Bar For Each; General Advice Unchanged From 2014 Draft, But Novel Mechanisms May Need More

February 9, 2022

ARPA-H Real-World Preview: House Hearing Addresses How Development Agency Would Fit Among Established Groups

February 9, 2022

Prevision Policy Clips | FDA Non-Opioid Acute Pain Guidance Includes Discussion Of “Opioid-Sparing” Effects

February 9, 2022

FDA Pilot Program On Unannounced Foreign Inspections Gets Another Push From GAO

February 9, 2022

Antibody-Drug Conjugate Complexity And Narrow Therapeutic Window Addressed In FDA Draft Guidance On Pharmacology Considerations

February 8, 2022

FDA Sintilimab Review Completes Public Re-Set On China-Only Trials: Lilly/Innovent ORIENT-11 Is Positive Study, Agency Says, But Inadequate For US Approval Of PD1 Inhibitor

February 8, 2022

Prevision Policy Clips | ARPA-H House Hearing Will Go On Despite Resignation Of Biden Chief Science Advisor Eric Lander

February 8, 2022
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2022 Prevision Policy. All Rights Reserved. Privacy Policy